Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-117 in Multifocal Motor Neuropathy
NCT05225675Phase 2Completed
- Sponsor
- argenx
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of empasiprubart in multifocal motor neuropathy (MMN), sponsored by argenx. Started Mar 2022; status: completed.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT05225675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225675.